Cancer Moonshot Launches in 2017

Cancer Moonshot Launches in 2017

Rare bipartisanship at the end of the Obama administration led to the passage of the 21st Century Cures Act championed by former Vice President Biden. The Act’s leading provision authorized $1.8 billion over 7 years for National Institutes of Health (NIH)-administered research into cancer. Also relevant to cancer therapeutics and diagnostics market development were the Act’s provisions for easing requirements and accelerating review of FDA submissions.


Revisiting the Cuban Healthcare Sector

Revisiting the Cuban Healthcare Sector

The death of longtime Cuban leader Fidel Castro is a potential watershed event for the economic course of the island nation. Diplomatic détente between Cuba and the United States was already underway earlier this year when Kalorama Information provided an overview of Cuban biopharmaceuticals, medical devices, and medical care. Through a combination of economic and healthcare policies prioritized under the Castro regime and the unrelenting pressure of globalization, Cuba may soon emerge as a significant player in global healthcare industries.


Cuban Biopharmaceuticals, Diagnostics and Medical Care Find Growing Interest from U.S. and International Healthcare Sectors

Cuban Biopharmaceuticals, Diagnostics and Medical Care Find Growing Interest from U.S. and International Healthcare Sectors

Remarkably, Cuba, despite near isolation from U.S. medical research, has managed notable advances in medical technology from its own industry. Cuban development of medical products such as cancer therapeutics , in vitro diagnostic (IVD) platforms and vaccines has occurred in the vacuum of U.S.-pioneered medical advances, but often manage only limited visibility internationally due to difficulties in investment. Reconciliation between the United States and Cuba has the potential to improve the di...